[144/A] Fulgent Genetics, Inc. SEC Filing

Rhea-AI Filing Summary

Fulgent Genetics (FLGT) insider sale notice under Form 144/A: An individual affiliated with Fulgent Genetics reported a proposed sale of 696 shares of common stock through Morgan Stanley Smith Barney on 08/25/2025, valued at approximately $14,965.08. The shares were acquired on 02/23/2023 upon vesting of restricted stock awarded as equity compensation.

The filer also reported three prior sales in the past three months totaling 3,008 shares with gross proceeds of $61,398.47. Outstanding common shares are listed as 30,609,044, making these transactions immaterial to total share count. The filing is a routine Rule 144 compliance notice and includes the customary representation that no undisclosed material adverse information is known.

Positive

• Rule 144 compliance: Filing provides required notice and transaction details, supporting regulatory transparency
• Clear acquisition origin: Shares were from restricted stock vesting, indicating compensation-related liquidity rather than open-market unusual activity

Negative

• Insider selling: Recent and proposed sales by an insider may be perceived negatively by some investors despite being small in scale

Insights

Securities Compliance Analyst

TL;DR: Routine insider Rule 144 filing documenting small-scale sales of vested restricted stock; compliance-focused and immaterial to capitalization.

This Form 144/A documents a planned sale of 696 shares and recent disposals totaling 3,008 shares by an insider who acquired the shares via restricted stock vesting. The aggregate values reported (~$14.97k planned; ~$61.4k realized) represent a negligible share of the ~30.6 million outstanding common shares. From a compliance perspective, the filing fulfills Rule 144 notice requirements and includes the standard certification regarding undisclosed material information. There are no red flags such as pledging, option exercises, or unusual consideration disclosed.

Corporate Governance Specialist

TL;DR: Insider selling is documented and transparent; size and nature (vested equity) indicate routine compensation monetization rather than governance concern.

The securities were acquired as equity compensation and sold through a broker, consistent with standard executive/employee liquidity events. The filing provides dates of acquisition and sale, payment nature, and broker details, supporting transparency. Given the small volumes relative to total shares outstanding and the disclosed origin as restricted stock vesting, this appears to be routine personal liquidity rather than a signal of company-specific issues. The signature block includes the required representation about material information, which preserves disclosure integrity.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144/A

144/A: Filer Information

Filer CIK
Filer CCC
Previous Accession Number Of The Filing
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144/A: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144/A: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC 1 New York Plaza, 38th FL New York NY 10004	696	14965.08	30609044	08/25/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144/A: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	02/23/2023	Resticted stock vest	Fulgent Genetics, Inc.			14573	02/23/2023	Equity compensation for services rendered

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144/A: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Jian Xie C/O Fulgent Genetics, Inc. 4399 Santa Anita Avenue El Monte CA 91731	Common Stock	05/27/2025	690	14196.92
Jian Xie C/O Fulgent Genetics, Inc. 4399 Santa Anita Avenue El Monte CA 91731	Common Stock	05/27/2025	1183	24271.47
Jian Xie C/O Fulgent Genetics, Inc. 4399 Santa Anita Avenue El Monte CA 91731	Common Stock	06/02/2025	1135	23030.08

144/A: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did the Form 144/A filed for FLGT disclose?

The filing disclosed a proposed sale of 696 common shares via Morgan Stanley Smith Barney on 08/25/2025, acquired on 02/23/2023 from restricted stock vesting.

How many shares were sold by the insider in the past three months?

The filer reported three sales totaling 3,008 shares on 05/27/2025 and 06/02/2025, with gross proceeds of $61,398.47.

What is the aggregate market value of the proposed sale?

The proposed sale of 696 shares has an aggregate market value of approximately $14,965.08.

Were the securities purchased or received as compensation?

Yes; the securities were acquired on 02/23/2023 as restricted stock vesting and described as equity compensation for services rendered.

Do these sales materially impact FLGT's share count?

No; the outstanding shares are listed as 30,609,044, so the reported sales are immaterial to total capitalization.